Sign In
Buy MYL
$15.86
+0 (+0%)
At Close: May 27, 2022
Biogen Falls on Patent Loss of MS Drug Tecfidera to Mylan
01:34pm, Friday, 19'th Jun 2020
The U.S. District Court of West Virginia gives a ruling against Biogen (BIIB) over a patent dispute with generic drugmaker Mylan pertaining to its best-selling multiple sclerosis drug, Tecfidera.
The Daily Biotech Pulse: Tiziana Snags A Patent Win, Decision Day For Nabriva And Evoke, IPOs
11:41am, Friday, 19'th Jun 2020
Here's a roundup of top developments in the biotech space over the last 24 hours.Scaling The Peaks (Biotech Stocks Hitting 52-week Highs June 18) * ADC Therapeutics SA (NYSE: ADCT) * Adverum Biotech
US STOCKS-S&P 500 closes nominally higher amid COVID-19 spikes, muted data
08:21pm, Thursday, 18'th Jun 2020
The S&P; 500 closed nominally higher on Thursday as investors weighed a resurgence in coronavirus infections and the possibility of a new round of shutdowns as well as data that suggested the U.S. eco
Mylan Wins District Court Decision Against Biogen's Tecfidera® Patent
08:04pm, Thursday, 18'th Jun 2020
Mylan N.V. (NASDAQ: MYL) today announced that the U.S. District Court for the Northern District of West Virginia invalidated Biogen's Tecfidera® patent, U.S. Patent No. 8,399,514, for lack of written
US STOCKS-Wall Street oscillates amid COVID-19 spikes, muted data
06:19pm, Thursday, 18'th Jun 2020
The tech-heavy Nasdaq was essentially flat. "It's not unusual after huge moves to trade sidewise," said Chuck Carlson, chief executive officer at Horizon Investment Services in Hammond, Indiana. Ini
US STOCKS-S&P 500 muted as virus cases rise, jobless claims weigh
05:31pm, Thursday, 18'th Jun 2020
The S&P; 500 was little changed on Thursday as coronavirus infections picked up again in parts of the United States and data showed an elevated level of weekly jobless claims, lending weight to predic
Biogen's stock drops toward 8-month low after disappointing Tecfidera patent ruling
04:24pm, Thursday, 18'th Jun 2020
Shares of Biogen Inc. sank 6.7% toward an 8-month low in morning trading Thursday, a district court in West Virginia invalidated a patent on Biogen's multiple sclerosis treatment Tecfidera, which is
US STOCKS-S&P 500, Dow muted as virus cases rise, jobless claims weigh
03:55pm, Thursday, 18'th Jun 2020
The S&P; 500 and the Dow were largely unchanged on Thursday as investors stayed on the sidelines amid an uptick in coronavirus infections in parts of the United States and an elevated level of weekly
Biogen Loses Court Decision to Mylan Over Multiple Sclerosis Drug
03:08pm, Thursday, 18'th Jun 2020
U.S. District Court judge rules that Mylan proved claims for Biogen's patent for Tecfidera are invalid for 'lack of written description.'
Biogen Stock Is Slumping After Judge Rules Against Its Biggest Drug
03:02pm, Thursday, 18'th Jun 2020
A federal-district court judge has invalidated Biogen’s patent on its multiple-sclerosis drug Tecfidera. Mylan could launch its generic next year, says RBC, unless it agrees otherwise in a settlemen
Biogen's stock drops toward 8-month low after disappointing Tecfidera patent ruling
02:59pm, Thursday, 18'th Jun 2020
Shares of Biogen Inc. sank 5.9% toward an 8-month low in morning trading Thursday, as investors reacted to reports that a West Virginia district court ruled in favor of Mylan N.V. by invalidating th
U.S. district court rules for Mylan in MS drug patent battle with Biogen
02:55pm, Thursday, 18'th Jun 2020
Tecfidera has been Biogen's main growth driver since it was launched in 2013, generating sales of $4.43 billion in 2019, accounting for nearly a third of total revenue. A court in the Northern Distri
Upjohn Announces Pricing of Senior Notes in Connection with the Proposed Combination of Mylan and Upjohn
10:59am, Thursday, 18'th Jun 2020
Upjohn Inc. ("Newco"), a wholly-owned subsidiary of Pfizer Inc. ("Pfizer") (NYSE: PFE), Upjohn Finance B.V. ("Finco"), a wholly-owned subsidiary of Newco, Pfizer and Mylan N.V. ("Mylan") (Nasdaq: MYL)
Upjohn Inc. -- Moody's assigns Baa3 unsecured rating to Upjohn/Viatris' US notes offering; outlook stable
01:13pm, Wednesday, 17'th Jun 2020
Moody's Investors Service ("Moody's") assigned Baa3 senior unsecured ratings to the notes offering of Upjohn Inc. ("Upjohn"). Upjohn is the mature branded business of Pfizer, Inc. ("Pfizer") that wil
Upjohn Finance B.V. -- Moody's assigns Baa3 unsecured rating to Upjohn/Viatris' Euro notes offering; outlook stable
09:12am, Wednesday, 17'th Jun 2020
Moody's Investors Service ("Moody's") assigned Baa3 senior unsecured ratings to the notes offering of Upjohn Finance B.V. ("Upjohn"). Upjohn is the mature branded business of Pfizer, Inc. ("Pfizer")
